<DOC>
	<DOCNO>NCT00358956</DOCNO>
	<brief_summary>This Phase II , open label study establish effect once-daily oral dos ZD6474 100mg subject locally advance metastatic hereditary medullary thyroid cancer standard therapeutic option available .</brief_summary>
	<brief_title>A Study To Assess ZD6474 ( ZACTIMAâ„¢ ) Monotherapy In Locally Advanced Metastatic Hereditary Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Provision write informed consent Previously confirm histological diagnosis locally advance metastatic hereditary medullary thyroid carcinoma without standard therapeutic option Aged 18 life expectancy 12 week The last dose prior chemo/radiation receive less 4 week start study therapy Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age , history arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>medullary thyroid cancer</keyword>
	<keyword>MTC</keyword>
	<keyword>hereditary medullary thyroid cancer</keyword>
	<keyword>thyroid cancer</keyword>
</DOC>